- cafead Jun 02, 2019 at 01:22: PM
via Key highlights for Sunday include:
AstraZeneca/Merck & Co will provide one of the highlights of Sunday at ASCO, with data from the phase 3 POLO trial as a maintenance treatment in metastatic pancreatic cancer with germline BRCA mutation. This will flesh out a top-line positive result announced earlier this year.
article source
AstraZeneca/Merck & Co will provide one of the highlights of Sunday at ASCO, with data from the phase 3 POLO trial as a maintenance treatment in metastatic pancreatic cancer with germline BRCA mutation. This will flesh out a top-line positive result announced earlier this year.
article source